Literature DB >> 30203583

Helicobacter pylori and nonmalignant upper gastrointestinal diseases.

Laimas Jonaitis1, Rinaldo Pellicano2, Limas Kupcinskas3.   

Abstract

The review of the most important recent publications concerning the relation of Helicobacter pylori with peptic ulcer disease (PUD), noninvestigated and functional dyspepsia, and gastroesophageal reflux disease (GERD) is presented. H. pylori remains the main etiopathogenetic factor in complicated and uncomplicated PUD. Nevertheless, the role of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin is increasing. The novel data did not confirm that PUD caused by NSAIDs and aspirin is less symptomatic. The role of glucocorticoids, immunosuppressants, and antidepressants seems to be of some importance. Although the involvement of H. pylori in functional dyspepsia is controversial, several data support the importance of H. pylori-induced gastritis in the pathogenesis of dyspeptic symptoms. Recent interventional studies have reported that H. pylori eradication improves dyspepsia mainly in areas with a high prevalence of this bacterium. Novel data regarding the relation of gastrointestinal peptides, ghrelin and obestatin, with H. pylori infection are also presented. Intriguing findings support the involvement of the gastric microbiota in the causation of chronic functional dyspepsia. Finally, some data concerning negative, positive, or neutral associations of H. pylori with gastroesophageal reflux disease (GERD) were published. In this context, today there is no evidence indicating that H. pylori eradication could worsen the symptoms or the course of GERD.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  dyspepsia; gastroesophageal reflux disease; peptic ulcer

Mesh:

Year:  2018        PMID: 30203583     DOI: 10.1111/hel.12522

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  10 in total

1.  Postinfectious onset in functional dyspepsia is a risk factor for weight loss.

Authors:  Jolien Schol; Florencia Carbone; Lieselot Holvoet; Karen Van den Houte; Esther Colomier; I-Hsuan Huang; Emidio Scarpellini; Tim Vanuytsel; Jan Tack
Journal:  J Gastroenterol       Date:  2022-01-29       Impact factor: 7.527

2.  Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial.

Authors:  Youn I Choi; Jun Won Chung; Dong Kyun Park; Kyoung Oh Kim; Kwang An Kwon; Yoon Jae Kim; Ja Young Seo
Journal:  World J Gastroenterol       Date:  2019-12-14       Impact factor: 5.742

3.  Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis.

Authors:  Rongqiang Liu; Qiuli Liu; Ying He; Wenqing Shi; Qianhui Xu; Qing Yuan; Qi Lin; Biao Li; Lei Ye; Youlan Min; Peiwen Zhu; Yi Shao
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

4.  The association between helicobacter pylori infection and erosive gastroesophageal reflux disease; a cross-sectional study.

Authors:  Ramin Niknam; Kamran Bagheri Lankarani; Mohsen Moghadami; Seyed Alireza Taghavi; Leila Zahiri; Mohammad Javad Fallahi
Journal:  BMC Infect Dis       Date:  2022-03-19       Impact factor: 3.090

Review 5.  Molecular Alterations in Gastric Intestinal Metaplasia.

Authors:  Paulius Jonaitis; Limas Kupcinskas; Juozas Kupcinskas
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

6.  Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia.

Authors:  Fahad Alsohaibani; Mohammed Alquaiz; Khalid Alkahtani; Hamad Alashgar; Musthafa Peedikayil; Abdulrahman AlFadda; Majid Almadi
Journal:  Saudi J Gastroenterol       Date:  2020 Mar-Apr       Impact factor: 2.485

7.  Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections.

Authors:  Chia-Jung Kuo; Chun-Wei Chen; Puo-Hsien Le; Jun-Te Hsu; Cheng-Yu Lin; Hao-Tsai Cheng; Ming-Yao Su; Chun-Jung Lin; Cheng-Tang Chiu
Journal:  Therap Adv Gastroenterol       Date:  2019-09-05       Impact factor: 4.802

Review 8.  Immune Response in H. pylori-Associated Gastritis and Gastric Cancer.

Authors:  Qingbin Niu; Jun Zhu; Xingquan Yu; Tao Feng; Hong Ji; Yuming Li; Weiwei Zhang; Baoguang Hu
Journal:  Gastroenterol Res Pract       Date:  2020-01-28       Impact factor: 2.260

9.  Myricetin as an Antivirulence Compound Interfering with a Morphological Transformation into Coccoid Forms and Potentiating Activity of Antibiotics against Helicobacter pylori.

Authors:  Paweł Krzyżek; Paweł Migdał; Emil Paluch; Magdalena Karwańska; Alina Wieliczko; Grażyna Gościniak
Journal:  Int J Mol Sci       Date:  2021-03-07       Impact factor: 6.208

10.  Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013-2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg).

Authors:  Paulius Jonaitis; Juozas Kupcinskas; Olga P Nyssen; Ignasi Puig; Javier P Gisbert; Laimas Jonaitis
Journal:  Medicina (Kaunas)       Date:  2021-06-23       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.